FDA Grants Orphan Drug Status to SLDB’s Novel Gene Therapy for Friedreich's Ataxia—What Does This Mean for Patients?
Market Chameleon (Tue, 13-Jan 8:38 AM)
Solid Biosciences Secures FDA Rare Pediatric Disease Designation for SGT-212, Marking Milestone in Friedreich's Ataxia Therapy Development
Market Chameleon (Mon, 1-Dec 8:37 AM)
